デフォルト表紙
市場調査レポート
商品コード
1785352

塞栓療法市場- 世界の産業規模、シェア、動向、機会、予測、製品別、適応症別、手技別、エンドユーザー別、地域別、競合別、2020-2030年

Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Procedure, By End User, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 190 Pages
納期
2～3営業日
カスタマイズ可能
塞栓療法市場- 世界の産業規模、シェア、動向、機会、予測、製品別、適応症別、手技別、エンドユーザー別、地域別、競合別、2020-2030年
出版日: 2025年08月06日
発行: TechSci Research
ページ情報: 英文 190 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

塞栓療法の世界市場規模は2024年に36億7,000万米ドルとなり、2030年までのCAGRは8.35%で、予測期間中に目覚ましい成長が予測されています。

塞栓療法は、標的部位への血流を選択的に制限する低侵襲治療です。異常な血管を閉塞させ、出血を効果的に抑制・停止させる血管内治療法です。緊急の重篤な出血症例において、塞栓療法は侵襲的手術に代わる有効な治療法として登場しました。この治療法は広く認知されるようになり、様々な臨床現場でインターベンショナルラジオロジストにより世界的に実施されています。特に、前立腺肥大症に対する前立腺動脈塞栓術（PAE）や体重減少に対する胃動脈塞栓術（GAE）のような最先端の手技では、塞栓療法の応用範囲は大きく広がっています。これらの治療法はいずれも、それぞれの疾患に対する効果的な治療法として役立っています。特にPAEは、前立腺肥大症による下部尿路症状（LUTS）に対処するため、世界中で年間800件以上の手術が行われています。塞栓療法は、変形性関節症、五十肩、使いすぎによる損傷など、筋骨格系の慢性疼痛管理に用いられています。子宮筋腫の治療への応用は、世界的に約85％の成功率を示しています。また、特定のタイプのがん、特に肝臓がんの治療にも利用されています。

市場概要
予測期間 2026-2030
市場規模：2024年 36億7,000万米ドル
市場規模：2030年 58億9,000万米ドル
CAGR：2025年～2030年 8.35%
急成長セグメント 塞栓剤
最大市場 北米

市場促進要因

対象患者数の増加

主な市場課題

厳しい規制

主要市場動向

買収と提携の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の塞栓療法市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品別（塞栓剤、マイクロカテーテル）
    • 適応症別（腫瘍学、血管学、動脈瘤学、泌尿器学、腎臓学）
    • 手順別（TACE、TARE）
    • エンドユーザー別（病院、クリニック、外来手術センター）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の塞栓療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の塞栓療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の塞栓療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の塞栓療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの塞栓療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Medtronic, PLC.
  • Microport Scientific
  • Boston Scientific Corporation
  • Stryker Corporation
  • Terumo Corporation
  • Penumbra, Inc.
  • Sirtex（CDH）
  • Johnson & Johnson
  • Abbott Laboratories Inc.
  • Balt Group（Balt Extrusion SAS）

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 4666

Global Embolotherapy Market was valued at USD 3.67 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.35% through 2030. Embolotherapy is a minimally invasive treatment that selectively restricts blood flow to targeted areas. It is an endovascular procedure utilized to occlude abnormal blood vessels, effectively controlling or ceasing bleeding. In urgent cases of severe hemorrhage, Embolotherapy has emerged as a viable alternative to invasive surgery. This treatment option has gained widespread recognition and is performed globally by interventional radiologists in various clinical settings. The applications of Embolotherapy have expanded significantly, particularly in cutting-edge procedures such as prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. Both of these procedures serve as effective treatment options for their respective conditions. PAE, in particular, is performed worldwide in over 800 procedures annually to address lower urinary tract symptoms (LUTS) caused by BPH. Embolotherapy is employed in the management of chronic pain conditions in the musculoskeletal system, including osteoarthritis, frozen shoulder, and overuse injuries. Its application in treating uterine fibroids has shown a success rate of approximately 85% globally. It is utilized in the treatment of specific types of cancer, notably liver cancer.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.67 Billion
Market Size 2030USD 5.89 Billion
CAGR 2025-20308.35%
Fastest Growing SegmentEmbolic Agents
Largest MarketNorth America

Key Market Drivers

Growing Target Patient Population

Cardiovascular disease (CVD) is a significant target ailment, and its importance and high prevalence have made it a focal point for research into successful and effective treatments. For instance, in May 2023, a study in Stroke, the American Stroke Association's leading journal, detailed a groundbreaking in-utero surgery to treat a fetal vein of Galen malformation-a rare, life-threatening cerebral vascular disorder. This successful intervention highlights the expanding target patient population for embolotherapy, driven by advances in prenatal diagnostics and treatment. As awareness and early detection grow, demand for innovative embolization solutions in both pediatric and fetal care is expected to rise. In 2017, peripheral vascular diseases affected over 200 million individuals worldwide. According to the same source, the prevalence of these diseases rises with age, with a prevalence rate of over 20% in those aged 80 and above. The increasing demand for Embolotherapy devices will be driven by the notable success rate and low postoperative complication rate associated with Embolotherapy procedures, coupled with the rising incidence of liver cancer and hepatocellular cancer. Liver cancer ranks as the fifth most common cancer in men and the ninth most common cancer in women, with over 840,000 new cases diagnosed worldwide in 2018 (source: World Cancer Research Fund). The kidney cancer incidence rates in the United Kingdom have witnessed a significant 42% increase over the past decade, with males experiencing a 38% incidence rate and females a 44% rate.

Key Market Challenges

Stringent regulations

Artificial embolization devices, including permanent microspheres used as artificial emboli (AED), are classified as medical devices. These devices function by physically closing vessels and are regulated as Class II vascular and neurovascular embolization devices in the United States. In the European Union, they are classified as Class IIB bland embolization devices under the medical device directive MDD 93/42/EEC. PVA particles have been used for over 40 years as a comparison device, serving as the basis for approval or authorization of later next-generation items due to their demonstrated general embolization of vessels.

Key Market Trends

Increasing Acquisitions and Collaborations

Increasing acquisitions and collaborations can indeed contribute to an increased demand for embolotherapy in the future. Collaborative efforts within the healthcare industry often lead to enhanced research, development, accessibility, and awareness of medical procedures like embolotherapy. Collaborations between pharmaceutical companies, medical device manufacturers, and research institutions can accelerate the research and development of new and improved embolotherapy techniques, devices, and materials. This can lead to innovations that increase the effectiveness and safety of embolotherapy procedures. Acquisitions and collaborations bring together the expertise of different entities. This multidisciplinary approach can lead to the creation of comprehensive and integrated embolotherapy solutions that cater to diverse patient needs.

Key Market Players

  • Medtronic, PLC
  • Microport Scientific Corp
  • Boston Scientific Corporation
  • Stryker Corporation
  • Terumo Corporation
  • Penumbra, Inc.
  • Sirtex (CDH)
  • Johnson & Johnson
  • Abbott Laboratories Inc.
  • Balt Group (Balt Extrusion SAS

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Embolotherapy Market, By Product:

  • Embolic Agents
    • Microspheres
    • Liquid Embolic Agents
    • Coil
  • Microcatheters

Embolotherapy Market, By Indication:

  • Oncology
  • Vascular
  • Aneurysm
  • Urology
  • Nephrology

Embolotherapy Market, By Procedure:

  • TACE
  • TARE

Embolotherapy Market, By End User:

  • Hospital
  • Clinics
  • Ambulatory Surgery Centres

Embolotherapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Embolic Agents, Microcatheters)
      • 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
    • 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
    • 5.2.3. By Procedure (TACE, TARE)
    • 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centers)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Embolotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Procedure
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Embolotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Procedure
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Embolotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Procedure
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Embolotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Procedure
        • 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By Procedure
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Embolotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Procedure
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Embolotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Procedure
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Embolotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Procedure
        • 7.3.3.2.4. By End User
    • 7.3.4. France Embolotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Procedure
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Embolotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Procedure
        • 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By Procedure
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Embolotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Procedure
        • 8.3.1.2.4. By End User
    • 8.3.2. India Embolotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Procedure
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Embolotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Procedure
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Embolotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Procedure
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Embolotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Procedure
        • 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By Procedure
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Embolotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Procedure
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Embolotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Procedure
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Embolotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Procedure
        • 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By Procedure
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Embolotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Procedure
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Embolotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Procedure
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Embolotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Procedure
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Medtronic, PLC.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Microport Scientific
  • 14.3. Boston Scientific Corporation
  • 14.4. Stryker Corporation
  • 14.5. Terumo Corporation
  • 14.6. Penumbra, Inc.
  • 14.7. Sirtex (CDH)
  • 14.8. Johnson & Johnson
  • 14.9. Abbott Laboratories Inc.
  • 14.10. Balt Group (Balt Extrusion SAS)

15. Strategic Recommendations

16. About Us & Disclaimer